Paclitaxel

製品コードS1150 別名：NSC 125973

Paclitaxel化学構造

分子量(MW)：853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(19)

カスタマーフィードバック(5)

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:yXYtKSzVyPUCuNFAxOjh5IN88US=> MVfTRW5ITVJ?
LC-2-ad NYHXXI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMECwN|E4KM7:TR?= MX3TRW5ITVJ?
RL95-2 NInPTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1yLkCwNFY3QCEQvF2= M3\IWnNCVkeHUh?=
MZ1-PC Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG3TWM2OD1yLkCwNFczQSEQvF2= NHTJ[mlUSU6JRWK=
TE-8 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HqTGlEPTB;MD6wNFEyPyEQvF2= M2LQWnNCVkeHUh?=
SW954 M1mwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nIeGlEPTB;MD6wNFEyQSEQvF2= NFzV[nlUSU6JRWK=
TE-11 NYrNUWFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILNfIZKSzVyPUCuNFAyOjNizszN NF:2coJUSU6JRWK=
PSN1 NXm0SndJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMECxN{DPxE1? NES1SItUSU6JRWK=
MOLT-4 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP2b|RJUUN3ME2wMlAxOTR7IN88US=> Ml34V2FPT0WU
697 NFz4XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOxTWM2OD1yLkCwNVUh|ryP MUTTRW5ITVJ?
ETK-1 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;1TWM2OD1yLkCwNVUzKM7:TR?= NF71UIdUSU6JRWK=
TE-10 M4G2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1yLkCwNVU1KM7:TR?= M2HpW3NCVkeHUh?=
HUTU-80 NYLmU4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5[GlEPTB;MD6wNFE3QCEQvF2= M3vOW3NCVkeHUh?=
NTERA-S-cl-D1 NI\6[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMECyNFkh|ryP M{[1W3NCVkeHUh?=
MFH-ino NYDqWpZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW5TWM2OD1yLkCwNlY5KM7:TR?= MYjTRW5ITVJ?
IA-LM NWPXNpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4c3c5UUN3ME2wMlAxOjhizszN MlfxV2FPT0WU
MC116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMECyPFkh|ryP M2TvdXNCVkeHUh?=
RKO M{PLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjtVVVKSzVyPUCuNFAzQThizszN NIHVXohUSU6JRWK=
MRK-nu-1 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMECyPVkh|ryP NHXXUXJUSU6JRWK=
VA-ES-BJ NGLQ[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nEPWlEPTB;MD6wNFMh|ryP MkPVV2FPT0WU
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7jTWM2OD1yLkCwN|A5KM7:TR?= MWLTRW5ITVJ?
BB30-HNC NGPxOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojBTWM2OD1yLkCwN|E1KM7:TR?= NWrzcnpkW0GQR1XS
ACN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\jTWM2OD1yLkCwN|E3KM7:TR?= MYrTRW5ITVJ?
TE-9 NEO2N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjHSGJGUUN3ME2wMlAxOzJ4IN88US=> NYrnN4x5W0GQR1XS
SIG-M5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD1yLkCwN|I4KM7:TR?= NX75OJBKW0GQR1XS
no-10 M2HjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHjTI1lUUN3ME2wMlAxOzZ{IN88US=> NXvxN2hRW0GQR1XS
EW-1 M{CzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDnOpNsUUN3ME2wMlAxOzdzIN88US=> NFnJTpdUSU6JRWK=
SK-LMS-1 M3LpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknqTWM2OD1yLkCwOFAyKM7:TR?= M2GzOXNCVkeHUh?=
GT3TKB NGfnRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsNXNiUUN3ME2wMlAxPDN2IN88US=> NYXHXVBQW0GQR1XS
ES4 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOwTWM2OD1yLkCwOFQ6KM7:TR?= NFK1dVVUSU6JRWK=
IMR-5 M1yyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC0OUDPxE1? MWHTRW5ITVJ?
NCI-H1648 NEXHSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEC0Olkh|ryP MXzTRW5ITVJ?
MV-4-11 NGnMRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEC0O|Uh|ryP MVzTRW5ITVJ?
SK-UT-1 NEPJXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiyXlVKSzVyPUCuNFA1QCEQvF2= MUTTRW5ITVJ?
NB13 M2j6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEC0PVEh|ryP MWPTRW5ITVJ?
DJM-1 M37QeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC1N{DPxE1? MkH0V2FPT0WU
ES8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWOVFKSzVyPUCuNFA2OzhizszN NXLYb5B5W0GQR1XS
TE-6 M2jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDlSGhUUUN3ME2wMlAxPTdizszN NXPTVXVbW0GQR1XS
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlruTWM2OD1yLkCwOVgzKM7:TR?= M1XOO3NCVkeHUh?=
TE-1 M{Pmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEC2NFYh|ryP NWLj[IR7W0GQR1XS
ATN-1 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEC2NFkh|ryP NI\WVIpUSU6JRWK=
A4-Fuk NXzTW5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXJblFKSzVyPUCuNFA3OTFizszN MoHmV2FPT0WU
ALL-PO MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPRR2drUUN3ME2wMlAxPjNizszN M1nOW3NCVkeHUh?=
BE-13 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5TWM2OD1yLkCwOlM3KM7:TR?= NFPOSo1USU6JRWK=
KM12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrPRmJKSzVyPUCuNFA3OzdizszN NIXHOY5USU6JRWK=
NOS-1 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nQRWlEPTB;MD6wNFY2KM7:TR?= NYXrXZUxW0GQR1XS
SW962 NUXiZmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEC2OlIh|ryP MV3TRW5ITVJ?
OCUB-M MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEC2OlIh|ryP NUiwSGk5W0GQR1XS
NCI-H510A NXfLb5ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHGWVhKSzVyPUCuNFA3PjVizszN MWPTRW5ITVJ?
EW-16 M1m3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf3OYJKSzVyPUCuNFA3QTRizszN NEO0Z4tUSU6JRWK=
KGN M{\Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEC3NVIh|ryP MmHEV2FPT0WU
LS-411N NYG2cXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLHPXh2UUN3ME2wMlAxPzF5IN88US=> MlX5V2FPT0WU
Becker NUPRe4xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLDTWM2OD1yLkCwO|Ih|ryP MXjTRW5ITVJ?
HC-1 NHjoO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Pue2lEPTB;MD6wNFczOSEQvF2= NXz5bWF2W0GQR1XS
CESS NGrEU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PF[mlEPTB;MD6wNFc{PyEQvF2= NVLhd3ByW0GQR1XS
KURAMOCHI M3PKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDDcI5yUUN3ME2wMlAxPzR6IN88US=> NH3lUllUSU6JRWK=
TGBC24TKB M3rqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEC3OVIh|ryP NGn5b3VUSU6JRWK=
SW982 NEP1fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHJTWM2OD1yLkCwO|Y3KM7:TR?= Mm\IV2FPT0WU
HCE-4 NUW4eHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj5NpNKSzVyPUCuNFA4PjdizszN M3PxVHNCVkeHUh?=
LOUCY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjtU2ExUUN3ME2wMlAxPzd3IN88US=> MkT5V2FPT0WU
8-MG-BA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zCSmlEPTB;MD6wNFc6PiEQvF2= MWPTRW5ITVJ?
HT-144 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13Cb2lEPTB;MD6wNFgh|ryP M3XaWHNCVkeHUh?=
LXF-289 M3PPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDoTWM2OD1yLkCwPFE5KM7:TR?= M2HxS3NCVkeHUh?=
RS4-11 NF;FfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3[po2UUN3ME2wMlAxQDN4IN88US=> NUe5Z5pQW0GQR1XS
DEL NWDmSIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XJ[mlEPTB;MD6wNFg1PSEQvF2= NEnRcHFUSU6JRWK=
OCI-AML2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3bHhKSzVyPUCuNFA5PTJizszN MX\TRW5ITVJ?
CCRF-CEM NH\hUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe5R2hRUUN3ME2wMlAxQDdzIN88US=> NHjFUo9USU6JRWK=
A388 NFPlflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDhSmptUUN3ME2wMlAxQDd2IN88US=> MX\TRW5ITVJ?
KNS-42 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O1c2lEPTB;MD6wNFg6OSEQvF2= NHPmcG1USU6JRWK=
OVCAR-4 NXP6dHNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO4R2xKSzVyPUCuNFA6ODRizszN NWLkUpd1W0GQR1XS
NCI-H1355 NFT6Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\wS5JKSzVyPUCuNFA6OTRizszN M4SzbHNCVkeHUh?=
BL-70 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLBTWM2OD1yLkCwPVMh|ryP NHXHXJNUSU6JRWK=
BL-41 NX3OT2ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETEfpRKSzVyPUCuNFA6OzRizszN NIm4fpFUSU6JRWK=
A101D NUXCcpl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W5N2lEPTB;MD6wNFk3KM7:TR?= NV3vW3Z1W0GQR1XS
HL-60 NHjDeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfhTWM2OD1yLkCwPVY3KM7:TR?= MWLTRW5ITVJ?
COR-L279 M2jld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW0UpNKSzVyPUCuNFA6QTlizszN NI\zU5RUSU6JRWK=
NCI-SNU-16 M3HUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HtcmlEPTB;MD6wNVAxQCEQvF2= NX7yT|BLW0GQR1XS
Calu-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1cmlEPTB;MD6wNVAyOiEQvF2= MkHaV2FPT0WU
SR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfBTWM2OD1yLkCxNFI3KM7:TR?= MnLyV2FPT0WU
QIMR-WIL NV;UVWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zTdmlEPTB;MD6wNVA{OyEQvF2= NGXWbWtUSU6JRWK=
LB647-SCLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XDUWlEPTB;MD6wNVA2OSEQvF2= MlvBV2FPT0WU
RPMI-8226 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXDc2V2UUN3ME2wMlAyOTB{IN88US=> MnSzV2FPT0WU
SK-PN-DW Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEGxNVIh|ryP MYnTRW5ITVJ?
SF268 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXoU4lKSzVyPUCuNFEyPTFizszN MXXTRW5ITVJ?
HD-MY-Z MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEGxOlMh|ryP NUjqOYJJW0GQR1XS
DOHH-2 NX\DcYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1yLkCxNlA{KM7:TR?= M3L4eHNCVkeHUh?=
SCC-3 NH7Jb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHtTWM2OD1yLkCxNlA1KM7:TR?= NYTqdHZVW0GQR1XS
ST486 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF65SplKSzVyPUCuNFEzODRizszN NHrEc3lUSU6JRWK=
NALM-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrIcllKSzVyPUCuNFEzOTRizszN MX7TRW5ITVJ?
NCI-H1436 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHNTWM2OD1yLkCxNlMyKM7:TR?= M{Dtc3NCVkeHUh?=
KE-37 NVHWPHlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvB[2ZKSzVyPUCuNFEzOzRizszN M4jEfXNCVkeHUh?=
RPMI-8402 M2ezdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\pUoJKSzVyPUCuNFEzPTZizszN M4rxU3NCVkeHUh?=
RXF393 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEGyOVch|ryP MlPHV2FPT0WU
KARPAS-45 NVi2U49RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewTWM2OD1yLkCxNlch|ryP NEnIeJFUSU6JRWK=
HOP-62 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEGyO|Yh|ryP NHXCbZNUSU6JRWK=
ES1 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPvTmNyUUN3ME2wMlAyOjh6IN88US=> NEfFfYdUSU6JRWK=
L-363 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW5TWM2OD1yLkCxN|UyKM7:TR?= M4fTfnNCVkeHUh?=
GI-1 NXnrb4ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XiVWlEPTB;MD6wNVM4OyEQvF2= MULTRW5ITVJ?
CTV-1 M3rL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4TWM2OD1yLkCxOFc5KM7:TR?= NEDicJNUSU6JRWK=
TE-5 NWTLdY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjxeVJ2UUN3ME2wMlAyPDl4IN88US=> Mmj2V2FPT0WU
SNU-C2B MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEG0PVYh|ryP NFfVW3FUSU6JRWK=
K-562 NE\kVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEG1NVYh|ryP NH;VfJJUSU6JRWK=
SNB75 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XoSGlEPTB;MD6wNVU1KM7:TR?= NEi1Z4xUSU6JRWK=
MOLT-13 NYr6[5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D6PGlEPTB;MD6wNVY{PyEQvF2= NUG0RoZxW0GQR1XS
LS-123 NVnLbIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK4foFHUUN3ME2wMlAyPjZ2IN88US=> NEP5PW5USU6JRWK=
NCI-SNU-5 M{Tscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYN3IxUUN3ME2wMlAyPzBzIN88US=> NIDGZolUSU6JRWK=
Daudi NGTVN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4SpVNUUN3ME2wMlAyPzB6IN88US=> M3LLWnNCVkeHUh?=
A253 NF71dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjkV3k1UUN3ME2wMlAyPzN6IN88US=> NXrPeoI4W0GQR1XS
TGBC1TKB NGrDbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzZVFVKSzVyPUCuNFE4PTJizszN NWLUUFVTW0GQR1XS
SJSA-1 M162cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG0TWM2OD1yLkCxO|Y4KM7:TR?= M2jPW3NCVkeHUh?=
NCCIT M3LCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHyTWM2OD1yLkCxO|Y6KM7:TR?= MYTTRW5ITVJ?
NCI-H69 M4HDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTkV|JtUUN3ME2wMlAyPzd6IN88US=> MmXOV2FPT0WU
SH-4 NYnQ[5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;VTWM2OD1yLkCxPFk2KM7:TR?= MnL6V2FPT0WU
HCC1187 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0[mlEPTB;MD6wNVkzPCEQvF2= NVLkT45pW0GQR1XS
HCC1599 NI\VUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jmZ2lEPTB;MD6wNlAzKM7:TR?= MXrTRW5ITVJ?
ONS-76 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEKwN|Yh|ryP NIXVPY9USU6JRWK=
KU812 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEKwN|kh|ryP Mmi4V2FPT0WU
ML-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zre2lEPTB;MD6wNlA1PyEQvF2= MUPTRW5ITVJ?
HCE-T NH3seVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml25TWM2OD1yLkCyNFkzKM7:TR?= NIjNfG1USU6JRWK=
NCI-H446 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nmVGlEPTB;MD6wNlEyOiEQvF2= MnHhV2FPT0WU
RPMI-6666 NXvhZXI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n4cGlEPTB;MD6wNlE1QSEQvF2= MWfTRW5ITVJ?
MOLT-16 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3wTWM2OD1yLkCyNVU{KM7:TR?= MljmV2FPT0WU
JiyoyeP-2003 NHXve2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHaTWM2OD1yLkCyNVc3KM7:TR?= NIjxdIZUSU6JRWK=
MHH-PREB-1 NVv4R|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEKxPVEh|ryP M1LFVnNCVkeHUh?=
MC-CAR NYP6XWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq2TWM2OD1yLkCyN|I3KM7:TR?= M37FenNCVkeHUh?=
BC-3 NHvKNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q2NWlEPTB;MD6wNlM1PCEQvF2= MmrEV2FPT0WU
KINGS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEKzOVUh|ryP Ml7nV2FPT0WU
PF-382 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rrZWlEPTB;MD6wNlM4QCEQvF2= M4L1[3NCVkeHUh?=
J-RT3-T3-5 M362W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXcpFpUUN3ME2wMlAzOzh|IN88US=> NVjmcFBuW0GQR1XS
SF539 NXzSOY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFb5JRUUN3ME2wMlAzPDBzIN88US=> NWPaTYlWW0GQR1XS
LB831-BLC M3zmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEK0PFUh|ryP NVnnSWtUW0GQR1XS
DMS-114 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W5RWlEPTB;MD6wNlUxOiEQvF2= MYjTRW5ITVJ?
LB1047-RCC MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEK1NUDPxE1? NXjRcmZ[W0GQR1XS
LB771-HNC MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvpb5ZKSzVyPUCuNFI2OzRizszN NGXRO3FUSU6JRWK=
BB65-RCC M3OxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEK1N|Qh|ryP MVHTRW5ITVJ?
BV-173 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT6NYdYUUN3ME2wMlAzPTV2IN88US=> NHO3SXpUSU6JRWK=
ARH-77 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEK2NFEh|ryP NFHlWY1USU6JRWK=
IST-MEL1 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITCe|ZKSzVyPUCuNFI3OjNizszN MkC0V2FPT0WU
NB1 M3HWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEK2PFch|ryP Ml70V2FPT0WU
EoL-1-cell MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTTUlJUUUN3ME2wMlAzPjh6IN88US=> NVftVGVsW0GQR1XS
KY821 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Yd4ZKSzVyPUCuNFI3QTdizszN NIjnRlhUSU6JRWK=
CMK MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jxe2lEPTB;MD6wNlc{PCEQvF2= MlvkV2FPT0WU
NCI-H2126 NWPZWJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;OR|NKSzVyPUCuNFI4PjhizszN Mo\ZV2FPT0WU
NCI-H526 NF;2e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEK4PVEh|ryP M1LLVXNCVkeHUh?=
COLO-684 M374fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTycplqUUN3ME2wMlAzQTB6IN88US=> MWjTRW5ITVJ?
NCI-H747 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qTWM2OD1yLkCyPVM{KM7:TR?= M3P2THNCVkeHUh?=
JAR NHruTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XhVGlEPTB;MD6wNlk1PiEQvF2= MoDsV2FPT0WU
MEG-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[3ZYJKSzVyPUCuNFI6PzhizszN NULOboFOW0GQR1XS
MONO-MAC-6 M3;NS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3OOYhKSzVyPUCuNFMxOjNizszN NY\HV5A6W0GQR1XS
IST-SL1 M13aR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\BdpFzUUN3ME2wMlA{ODR{IN88US=> M{\DdnNCVkeHUh?=
CPC-N MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEOwO|kh|ryP MoHYV2FPT0WU
NCI-H1963 NHzwXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjjSmJzUUN3ME2wMlA{OTNzIN88US=> Mo\kV2FPT0WU
K052 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEOyOFch|ryP NXvGRZE{W0GQR1XS
KM-H2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMEOzNFch|ryP NEnlPJlUSU6JRWK=
TE-12 M{DLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1yLkCzN|A6KM7:TR?= M13VfnNCVkeHUh?=
TK10 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW2d2lKSzVyPUCuNFM{PTZizszN NVP5O|dXW0GQR1XS
NMC-G1 NEOx[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPh[pMzUUN3ME2wMlA{PDV{IN88US=> M2fHTnNCVkeHUh?=
no-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q1U2lEPTB;MD6wN|Q4QCEQvF2= NHj1RnpUSU6JRWK=
NCI-H524 NIfJWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5TWM2OD1yLkCzOVI6KM7:TR?= MlftV2FPT0WU
MHH-CALL-2 NUjqSlFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEO1OlIh|ryP NGSzRldUSU6JRWK=
GB-1 M3\aWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLyTWM2OD1yLkCzOkDPxE1? NXrKe|RlW0GQR1XS
OPM-2 M13NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEO2O|Mh|ryP NGr5T5FUSU6JRWK=
RH-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEO4NVkh|ryP NEexVW1USU6JRWK=
NCI-H64 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;UUXZWUUN3ME2wMlA{QDV5IN88US=> MV3TRW5ITVJ?
EVSA-T NEnqWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny5TWM2OD1yLkCzPVI{KM7:TR?= NGH1epBUSU6JRWK=
KARPAS-299 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHqVmp5UUN3ME2wMlA{QThizszN MXvTRW5ITVJ?
MZ7-mel MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LySWlEPTB;MD6wOFA1KM7:TR?= NIDteYRUSU6JRWK=
LB373-MEL-D MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T1RmlEPTB;MD6wOFExPSEQvF2= MmfhV2FPT0WU
HEL NVH2WXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrqW4tKSzVyPUCuNFQyPCEQvF2= NGjy[I5USU6JRWK=
SW872 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M321d2lEPTB;MD6wOFIyKM7:TR?= MVnTRW5ITVJ?
DU-4475 NFTObYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3fmlEPTB;MD6wOFI1PCEQvF2= NVe3fnBpW0GQR1XS
IST-SL2 NHHoTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMESyO|Uh|ryP NIDs[5FUSU6JRWK=
NCI-H82 NIOy[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMESzNFch|ryP Mo\oV2FPT0WU
LC4-1 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHWTWM2OD1yLkC0N|UyKM7:TR?= NHqzSmVUSU6JRWK=
HDLM-2 NVXDPVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rybGlEPTB;MD6wOFM6OiEQvF2= MXLTRW5ITVJ?
MMAC-SF MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzpSWNKSzVyPUCuNFQ2OzRizszN NEG0fohUSU6JRWK=
L-540 M17CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMES2N|kh|ryP MV3TRW5ITVJ?
MZ2-MEL NHLSOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvZS|dRUUN3ME2wMlA1PzR{IN88US=> NYHWcWtyW0GQR1XS
LU-134-A MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DkRmlEPTB;MD6wOFc4OyEQvF2= MnPmV2FPT0WU
UACC-257 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS1R|F{UUN3ME2wMlA1QDR7IN88US=> NWPtZ2RMW0GQR1XS
NCI-H1581 NH:1XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf4WZdKSzVyPUCuNFQ6PTNizszN NVL1W3p5W0GQR1XS
NB17 NXzZZ3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDuNGY4UUN3ME2wMlA1QTd7IN88US=> M2HaVHNCVkeHUh?=
SBC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEWwOFIh|ryP NGHyNoZUSU6JRWK=
TALL-1 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnsU3F6UUN3ME2wMlA2ODR3IN88US=> NYL2dJhtW0GQR1XS
NCI-H1304 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEWyNFgh|ryP NIXyRotUSU6JRWK=
NEC8 NWL1V|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T3TWlEPTB;MD6wOVI5PiEQvF2= MX7TRW5ITVJ?
CAL-148 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H3SmlEPTB;MD6wOVQ{QSEQvF2= NX\XdZR4W0GQR1XS
CGTH-W-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGVFhSUUN3ME2wMlA2PDR7IN88US=> MkDLV2FPT0WU
NCI-H889 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M362bGlEPTB;MD6wOVU6OiEQvF2= NUTKfJd5W0GQR1XS
GR-ST MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEW2NlEh|ryP MnTKV2FPT0WU
KARPAS-422 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3ZWlEPTB;MD6wOVY2KM7:TR?= NUTqc2JpW0GQR1XS
RPMI-8866 NWfqXlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\MbmlEPTB;MD6wOVcyOiEQvF2= MXnTRW5ITVJ?
SCLC-21H NYTTWZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTkTWM2OD1yLkC1PFg1KM7:TR?= NHm4ZWRUSU6JRWK=
COR-L88 NVzrd2NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PTU2lEPTB;MD6wOVkzPyEQvF2= M4fIXnNCVkeHUh?=
LU-139 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLVe5h[UUN3ME2wMlA2QTh4IN88US=> MoLxV2FPT0WU
SF126 NXmzO41zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nldGlEPTB;MD6wOlE{OyEQvF2= M2PU[nNCVkeHUh?=
NCI-H1882 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwME[0NlQh|ryP NF2wbXVUSU6JRWK=
EW-24 M13vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrZmlEPTB;MD6wOlQ5OyEQvF2= MmfJV2FPT0WU
CP67-MEL M{nN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrmWYJKSzVyPUCuNFY5OSEQvF2= MUDTRW5ITVJ?
DG-75 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXTTWM2OD1yLkC2PFk6KM7:TR?= M3fvdnNCVkeHUh?=
LOXIMVI NF32SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vSdmlEPTB;MD6wO|AzQCEQvF2= NFfsfYZUSU6JRWK=
HH NWPsZXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH1SZFKSzVyPUCuNFcyPTdizszN M3HMc3NCVkeHUh?=
K5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRNlRiUUN3ME2wMlA4OjJ4IN88US=> MXTTRW5ITVJ?
EC-GI-10 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7veHBFUUN3ME2wMlA4OjV5IN88US=> M1TxcHNCVkeHUh?=
SK-N-DZ NHn2OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHQTWM2OD1yLkC3N|A4KM7:TR?= M1;sPHNCVkeHUh?=
A3-KAW Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq3[HJKSzVyPUCuNFc{PTFizszN M3PUUHNCVkeHUh?=
MLMA M{Lk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEe0OlUh|ryP NFrMUZFUSU6JRWK=
LB996-RCC NV7j[VJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWyfpdKSzVyPUCuNFc4ODdizszN MWHTRW5ITVJ?
OS-RC-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEe3OFgh|ryP MmjHV2FPT0WU
CTB-1 NGrGSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXMSFBKSzVyPUCuNFc5OSEQvF2= MULTRW5ITVJ?
IST-MES1 NVvYZnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEe5NVIh|ryP NGq3WHBUSU6JRWK=
LS-1034 NETP[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEiwN|Uh|ryP M{fKbXNCVkeHUh?=
HT M2nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MU3FLUUN3ME2wMlA5ODh4IN88US=> M3jsZ3NCVkeHUh?=
NCI-H2141 NHzHNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy5WVRJUUN3ME2wMlA5OSEQvF2= M{jWd3NCVkeHUh?=
LB2518-MEL NV;Ye29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16yRmlEPTB;MD6wPFE1OSEQvF2= NIDtSWtUSU6JRWK=
GI-ME-N NG[5PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfPTWM2OD1yLkC4OFUzKM7:TR?= MVTTRW5ITVJ?
TGW NX3sWXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEi2NFch|ryP MornV2FPT0WU
SK-NEP-1 NWHpcGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEi2OFEh|ryP Mli1V2FPT0WU
NOMO-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DZNWlEPTB;MD6wPVI4PSEQvF2= M3PNOnNCVkeHUh?=
ES6 NI\pbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XveGlEPTB;MD6wPVU5QSEQvF2= MmDBV2FPT0WU
NCI-H209 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEm3PFYh|ryP NWTq[XBRW0GQR1XS
GAK M4TkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXiOphKSzVyPUCuNVAyPiEQvF2= NVvEZ2RUW0GQR1XS
BC-1 NWL3bVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P5T2lEPTB;MD6xNFM3OSEQvF2= NWCxe4VmW0GQR1XS
KLE MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD1yLkGwOFQ{KM7:TR?= NX7rUopFW0GQR1XS
EW-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr4Wo1KSzVyPUCuNVA6QCEQvF2= NHSyfHpUSU6JRWK=
NKM-1 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMUGxJO69VQ>? NW\xcoZYW0GQR1XS
D-336MG M4S3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ldWlEPTB;MD6xNVI1PCEQvF2= M1O1XnNCVkeHUh?=
NB69 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxcmlEPTB;MD6xNVMxOSEQvF2= NYj6XmZyW0GQR1XS
D-263MG MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqxbZUxUUN3ME2wMlEyPzF{IN88US=> MkH2V2FPT0WU
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMUKyPVEh|ryP NGjEZnNUSU6JRWK=
NCI-H1155 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUK1OVgh|ryP MljrV2FPT0WU
BOKU M4f6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK1dVNKSzVyPUCuNVI2PzlizszN MVXTRW5ITVJ?
LAMA-84 M33s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fa[GlEPTB;MD6xNlk6KM7:TR?= M{HjcXNCVkeHUh?=
Raji MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrGOJlKSzVyPUCuNVMyOTdizszN M4rMNHNCVkeHUh?=
LU-65 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUOzNFch|ryP MVTTRW5ITVJ?
NCI-H187 NVTieZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj0TWM2OD1yLkGzPVI1KM7:TR?= MWLTRW5ITVJ?
GCIY NEfZO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3OOVFKSzVyPUCuNVQ6ODFizszN NWG2dlk3W0GQR1XS
NCI-H2107 M1voZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvIRXBQUUN3ME2wMlE2ODhizszN NFnEUZRUSU6JRWK=
NCI-H1522 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHvc5JKSzVyPUCuNVUzPjZizszN MVTTRW5ITVJ?
NB6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dj[2lEPTB;MD6xOVYzOyEQvF2= NYnpWGI5W0GQR1XS
EM-2 NFPYc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M323T2lEPTB;MD6xOVcxPiEQvF2= MmHkV2FPT0WU
HCC2218 NY\zRXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfi[HdKSzVyPUCuNVU6QCEQvF2= Mn7LV2FPT0WU
NCI-H748 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwWGlEPTB;MD6xOlM4PiEQvF2= NEHLdIxUSU6JRWK=
MS-1 NInrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMU[1N|ch|ryP Mmr1V2FPT0WU
NB5 NWC3O45UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLnXZJKSzVyPUCuNVY2QTdizszN NUfTPWZ5W0GQR1XS
OMC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGUWg1UUN3ME2wMlE3Pjh6IN88US=> MXvTRW5ITVJ?
NCI-H345 NGTsPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1cXRKSzVyPUCuNVY6OjhizszN MXXTRW5ITVJ?
L-428 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMU[5OFUh|ryP M3PXenNCVkeHUh?=
SCH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTKRm16UUN3ME2wMlE5Pjh3IN88US=> NEPtPXFUSU6JRWK=
NCI-H1417 M1XJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjIfmo4UUN3ME2wMlE6OjJ5IN88US=> NXnYRXI{W0GQR1XS
COLO-320-HSR M2\kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzzTWM2OD1yLkG5OVMzKM7:TR?= MV\TRW5ITVJ?
BT-474 NHr6cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHPTWM2OD1yLkKwPFkzKM7:TR?= M17uSHNCVkeHUh?=
GDM-1 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37pWWlEPTB;MD6yNVk4OSEQvF2= NW\pR2loW0GQR1XS
NCI-H2196 M3LvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLrTWM2OD1yLkKyNlM2KM7:TR?= NI[3SlhUSU6JRWK=
KP-N-RT-BM-1 NF;OWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT1TWM2OD1yLkKyN|Q6KM7:TR?= NYrFfYVTW0GQR1XS
KNS-81-FD Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMkK5OVgh|ryP NFrIT4hUSU6JRWK=
COLO-668 NHX3ZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;CdI1KSzVyPUCuNlM3PzVizszN M3\ObHNCVkeHUh?=
C2BBe1 NFTDc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMk[3OFch|ryP NH[zXZRUSU6JRWK=
Ramos-2G6-4C10 M3\teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMk[5OVQh|ryP NYfTPFB1W0GQR1XS
CAS-1 NUT0VHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rjbmlEPTB;MD6yO|A6PiEQvF2= MknmV2FPT0WU
GOTO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lwb2lEPTB;MD6yO|g6PCEQvF2= MmDwV2FPT0WU
LP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkiwOVch|ryP NEDJSmZUSU6JRWK=
NCI-SNU-1 M{nRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPTcldKSzVyPUCuNlk1OjJizszN M33adHNCVkeHUh?=
EB-3 NIPqbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDyepNqUUN3ME2wMlI6QTd7IN88US=> NF\lTVdUSU6JRWK=
MHH-NB-11 M{LxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4fWlEPTB;MD6zNFQxOiEQvF2= NVvjO5c4W0GQR1XS
SK-N-FI MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL3boNKSzVyPUCuN|E3QTJizszN NUX1cZV4W0GQR1XS
HCC2157 NGLLc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwM{O5NVMh|ryP M{eySHNCVkeHUh?=
SIMA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfDTWM2OD1yLkO0OVgyKM7:TR?= MoC2V2FPT0WU
MDA-MB-134-VI M3;1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTNcIJKSzVyPUCuN|Y6OjhizszN MWXTRW5ITVJ?
NCI-H1694 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwM{eg{txO Ml\QV2FPT0WU
EHEB NEf3bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXzSpNpUUN3ME2wMlM6ODh3IN88US=> NUjL[5RjW0GQR1XS
U-266 NEXUUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwenpFUUN3ME2wMlM6QDR4IN88US=> NEfpSnZUSU6JRWK=
LC-1F MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjSZYNKSzVyPUCuOFM4PjVizszN NHjRcG5USU6JRWK=
SHP-77 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTxWWxbUUN3ME2wMlQ4QDV3IN88US=> NXTQT2lYW0GQR1XS
LS-513 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNEmzNFch|ryP MoXJV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作（参考用のみ）

細胞試験：

[1]
+ 展開
  • 細胞株： Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度： 0.1-100 pM
  • 反応時間： 72 hours
  • 実験の流れ：

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験：

[5]
+ 展開
  • 動物モデル： Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤： Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量： 20 mg/kg
  • 投与方法： Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。 		2.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14
CAS No. 33069-62-4
保管 粉
in solvent
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694002 Recruiting Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) August 9 2018 Phase 2
NCT03275818 Recruiting Tumor Desmoplastic Small Round Cell Adult|Tumor Desmoplastic Small Round Cell Childhood|Sarcoma Ewing|Sarcoma|Desmoid Grupo Espanol de Investigacion en Sarcomas May 9 2017 Phase 2
NCT03057600 Active not recruiting Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer Calithera Biosciences Inc May 9 2017 Phase 2
NCT02775435 Active not recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT02415023 Completed Gastric Cancer Hutchison Medipharma Limited November 9 2014 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答：

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2：

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答：

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

selleck catalog

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • Docetaxel

    Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Vincristine sulfate

    Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

  • Nocodazole

    Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID